Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 March 2020 | Story Valentino Ndaba | Photo Sonia Small
Human Rights
Human Rights Month is a time to reflect on the past and celebrate the present.

On 21 March 2020, South Africa will celebrate Human Rights Day. The day has a specific meaning, as it commemorates the Sharpeville massacre which took place on 21 March 1960 in Sharpeville in the Vaal. After the community demonstrated against the pass laws, about 7,000 protesters went to the local police station where the South African Police opened fire on the crowd, killing 69 people and injuring 180.
 
The past, although dark and tragic, holds the power to propel a nation forward. Rector and Vice-Chancellor of the University of the Free State (UFS), Prof Francis Petersen, said: “In remembering this day, we have the opportunity to reflect on progress in the promotion and protection of human rights in South Africa.”
 
Prof Petersen expressed pride in the great strides made at the UFS in this regard and which are cause for celebration. “As a university community, let us join the rest of the country this month and celebrate the rights of all people to be protected from violation, irrespective of gender, race, sexual orientation, religion, etc. Let us observe this day and stand together to promote respect for human rights,” he said.

Policies with a purpose
UFS is guided by principles of non-discrimination and values which seek to uphold the rights of all humans as stipulated in the Constitution of the Republic of South Africa. Staff, students, and the general public enjoy the protection and dignity with policies such as Anti-Discrimination, Promotion of Equality and Social Justice Policy, the Sexual Harassment, Sexual Misconduct and Sexual Violence Policy, the Social Support Policy, as well as the Student Pregnancy Policy.

The objective of the Anti-Discrimination, Promotion of Equality, and Social Justice Policy is to clarify, deepen and promote an understanding of equality, social justice and unfair discrimination among the university community. In addition to other aims, it seeks to identify and promote an understanding of barriers to equality, as well as the various forms and practices of unfair discrimination that may occur. Preventing and eradicating such practices, identifying bullying practices within the various vertical and horizontal relationships at the university, is the policy’s ultimate mandate.

In a country plagued by gender-based violence and related crimes, the Sexual Harassment, Sexual Misconduct and Sexual Violence Policy becomes all the more significant. The policy’s purpose includes establishing a safe and enabling environment, free from sexual harassment, sexual misconduct and sexual violence, for all UFS community members. Support for victims and putting disciplinary procedures for perpetrators in place is a high priority within the policy. 

Human Rights are of utmost importance for a transforming institution such as ours. Hence, the Centre for Universal Access and Disability Support (CUADS) recently released the Social Support Policy Draft for public input. Its overarching goal is to establish an institutional climate and conditions that enable the UFS to retain its students and improve their chances of success by providing appropriate social support. 
 
As far as the Student Pregnancy Policy is concerned, creating conditions that are conducive for academic success and wellbeing during pregnancy is one of the ways in which the university upholds the human rights of mothers-to-be. The policy also ensures that pregnant students are not excluded from academic programmes, residences and other university activities.



News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept